These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23206263)

  • 41. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.
    Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM
    J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Guidelines and best practices for appropriate use of dalfampridine in managed care populations.
    Miravalle AA
    Am J Manag Care; 2011 May; 17 Suppl 5 Improving():S154-60. PubMed ID: 21761954
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MSmonitor-plus program and video calling care (MPVC) for multidisciplinary care and self-management in multiple sclerosis: study protocol of a single-center randomized, parallel-group, open label, non-inferiority trial.
    Hoving M; Jongen PJ; Evers SMAA; Edens MA; Zeinstra EMPE
    BMC Neurol; 2022 Nov; 22(1):423. PubMed ID: 36371162
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1857-65. PubMed ID: 24993136
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents.
    Amato MP
    Expert Opin Pharmacother; 2004 Oct; 5(10):2115-26. PubMed ID: 15461547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
    Prescott JD; Factor S; Pill M; Levi GW
    J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.
    Burkhard A; Toliver J; Rascati K
    J Manag Care Spec Pharm; 2021 Jul; 27(7):915-923. PubMed ID: 34185555
    [No Abstract]   [Full Text] [Related]  

  • 50. Gender differences in self-reported symptom awareness and perceived ability to manage therapy with disease-modifying medication among commercially insured multiple sclerosis patients.
    Vlahiotis A; Sedjo R; Cox ER; Burroughs TE; Rauchway A; Lich R
    J Manag Care Pharm; 2010 Apr; 16(3):206-16. PubMed ID: 20331325
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Siponimod for multiple sclerosis.
    Cao L; Li M; Yao L; Yan P; Wang X; Yang Z; Lao Y; Li H; Yang K; Li K
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013647. PubMed ID: 34783010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic decision making in a new drug era in multiple sclerosis.
    Keegan BM
    Semin Neurol; 2013 Feb; 33(1):5-12. PubMed ID: 23709208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacoeconomics of synthetic therapies for multiple sclerosis.
    D'Amico E; Chisari CG; Gitto L; Zanghì A; Toscano S; Patti F
    Expert Opin Pharmacother; 2019 Aug; 20(11):1331-1340. PubMed ID: 31090469
    [No Abstract]   [Full Text] [Related]  

  • 54. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
    Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
    J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States.
    Nicholas J; Halpern R; Ziehn M; Peterson-Brandt J; Leszko M; Deshpande C
    J Med Econ; 2020 Aug; 23(8):885-893. PubMed ID: 32338098
    [No Abstract]   [Full Text] [Related]  

  • 56. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Managed care aspects of managing multiple sclerosis.
    Mathis AS
    Am J Manag Care; 2013 Feb; 19(2 Suppl):S28-34. PubMed ID: 23544718
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effectiveness of school-based family asthma educational programs on the quality of life and number of asthma exacerbations of children aged five to 18 years diagnosed with asthma: a systematic review protocol.
    Walter H; Sadeque-Iqbal F; Ulysse R; Castillo D; Fitzpatrick A; Singleton J
    JBI Database System Rev Implement Rep; 2015 Oct; 13(10):69-81. PubMed ID: 26571284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interventions to support risk and benefit understanding of disease-modifying drugs in Multiple Sclerosis patients: A systematic review.
    Reen GK; Silber E; Langdon DW
    Patient Educ Couns; 2017 Jun; 100(6):1031-1048. PubMed ID: 28108125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.